Skip to main content
Search

Developing therapeutic monoclonal antibodies (mAbs) and antibody-based products 1

Part 1 of 2
Published on November 30, 2022   32 min

A selection of talks on Pharmaceutical Sciences

Please wait while the transcript is being prepared...
0:00
Hello everyone. Thanks for joining Part 1 of my talk. Today we will be looking at the development of monoclonal antibodies or mAbs in short and several antibody-based products. My name is Veysel Kayser. I work at the University of Sydney as an associate professor in the School of Pharmacy. There are many different terms in the literature for biologics, such as biotherapeutics, biologic molecules, biomedicine, etc. Although these terms refer to slightly different things depending on the context, in this lecture I'll use them interchangeably.
0:35
Outline of the lecture is listed in this slide. First, we will learn about various terms and phrases and talk about why they are important. Then we will compare biologics with small molecules and discuss their attributes. Then talk about mAbs, different types of antibody-based biologics and new developments including antibody-drug conjugates or ADCs by specifics and immune checkpoint inhibitors.
1:04
Biologics are quite different from small molecules and they cannot be synthesized by chemical synthesis. So active substance, which is mostly a protein such as an antibody, is produced or derived from a living organisms or in cell culture. In the case of antibodies, mammalian cell culture for instance, chore or excels are used. They have different sizes, for example many hormones and peptides such as insulin are small biologics, but some biologics are large proteins, for example monoclonal antibodies, or even cells like T-cells. Most biologics are proteins and they are produced recombinantly in mammalian cell culture.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Developing therapeutic monoclonal antibodies (mAbs) and antibody-based products 1

Embed in course/own notes